Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $41.25.
RCUS has been the topic of several research reports. Mizuho dropped their price target on Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, January 30th. Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Arcus Biosciences in a research report on Thursday, February 22nd. Finally, Truist Financial restated a “buy” rating and set a $50.00 price target on shares of Arcus Biosciences in a research report on Monday, March 25th.
Get Our Latest Analysis on Arcus Biosciences
Insider Buying and Selling at Arcus Biosciences
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of RCUS. Decheng Capital LLC purchased a new position in shares of Arcus Biosciences in the fourth quarter worth $16,613,000. Barclays PLC grew its holdings in shares of Arcus Biosciences by 183.4% in the third quarter. Barclays PLC now owns 470,776 shares of the company’s stock worth $8,451,000 after acquiring an additional 304,683 shares during the period. FMR LLC grew its holdings in shares of Arcus Biosciences by 4.9% in the third quarter. FMR LLC now owns 4,780,052 shares of the company’s stock worth $85,802,000 after acquiring an additional 222,280 shares during the period. Vanguard Group Inc. grew its holdings in shares of Arcus Biosciences by 4.2% in the fourth quarter. Vanguard Group Inc. now owns 4,680,716 shares of the company’s stock worth $89,402,000 after acquiring an additional 186,898 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Arcus Biosciences by 11.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,594,609 shares of the company’s stock worth $30,459,000 after acquiring an additional 158,094 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.
Arcus Biosciences Stock Performance
Shares of RCUS stock opened at $14.73 on Friday. Arcus Biosciences has a fifty-two week low of $12.95 and a fifty-two week high of $25.47. The firm has a market cap of $1.34 billion, a P/E ratio of -3.55 and a beta of 0.81. The business’s 50 day moving average price is $17.51 and its 200-day moving average price is $16.62.
Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($1.08) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.01. Arcus Biosciences had a negative return on equity of 57.17% and a negative net margin of 262.39%. The company had revenue of $31.00 million for the quarter, compared to analyst estimates of $28.30 million. During the same period in the previous year, the company posted ($0.93) earnings per share. The firm’s revenue was down 8.8% on a year-over-year basis. As a group, equities analysts predict that Arcus Biosciences will post -3.59 EPS for the current year.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Read More
- Five stocks we like better than Arcus Biosciences
- Golden Cross Stocks: Pattern, Examples and Charts
- Hasbro’s Management Made All the Right Calls This Quarter
- How to Calculate Return on Investment (ROI)
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.